FDA Extends Enforcement Discretion On Free Phytosterol Health Claims
This article was originally published in The Tan Sheet
Executive Summary
FDA will give firms a year to relabel or reformulate dietary supplements with nonesterified phytosterols to comply with a proposed rule that overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease.
You may also be interested in...
In Brief
FDA extends phytosterol enforcement discretion; Perrigo debuts Claritin-D 12 Hour equivalent; Reckitt sells Indian personal care brands acquired from Paras; Ocean Nutrition Canada gets vertical; more news In Brief.
Pfizer Proposes Criteria To Allow Free Phytosterol CHD Reduction Claim
FDA should allow CHD reduction claims for nonesterified phytosterol supplements to that disperse efficiently from tablet form and help block cholesterol uptake, Pfizer argues in comments to the agency.
Pfizer Proposes Criteria To Allow Free Phytosterol CHD Reduction Claim
FDA should allow CHD reduction claims for nonesterified phytosterol supplements to that disperse efficiently from tablet form and help block cholesterol uptake, Pfizer argues in comments to the agency.